Navigation Links
Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics' Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
Date:12/10/2007

- Company Plans to Initiate Phase IIa Study of NGX426 in Acute Migraine in

First Half of 2008 -

LA JOLLA, Calif., Dec. 10 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today reported pharmacokinetic data obtained in a Phase I maximum tolerated dose clinical trial of NGX426, the oral prodrug of tezampanel, show that the area under the curve (AUC), which represents the total amount of drug absorbed by the body, of a single, 80 mg, oral dose of NGX426 is comparable to the AUC of a single, 40 mg, subcutaneous dose of tezampanel.

With the recently demonstrated efficacy of 40 mg of tezampanel in a Phase IIb clinical trial in acute migraine, the comparable AUCs suggest that NGX426 also may be effective in treating acute migraine headache. TorreyPines Therapeutics plans to initiate a Phase IIa study of NGX426 in acute migraine in the first half of 2008.

"These findings with the oral form of tezampanel are very encouraging, especially when looked at in conjunction with the data from our evaluation of the subcutaneous form," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines Therapeutics. "These data fully support the continued development of NGX426, which, as an oral prodrug, can provide an additional route of administration for tezampanel to acute migraine sufferers."

Initiated earlier this year, this double-blind, placebo-controlled trial enrolled normal healthy adult volunteers in sequential, dose-escalating cohorts. The Phase I data show that single, oral doses of NGX426 from 40 mg to 90 mg are safe and well-tolerated. TorreyPines Therapeutics is amending the Phase I clinical trial protocol to extend the dosing range beyond 90 m
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
3. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
4. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
5. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
6. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
(Date:8/28/2015)... 28, 2015  IP Shakti, LLC, today announced that it ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... new corporate identity signifies our transformation into a company focused ... platform for patent claim validity." ... proprietary AIA Shield™ platform, the Company commenced a corporate re-branding ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... RATON, Fla., Sept. 15 Watermark Medical , ... the sleep-disordered breathing market, has expanded the market reach ... strategic alliances with three leading sleep solution providers in ... SleepQuest , a national provider of comprehensive sleep apnea ...
... Sept. 15 ViroPharma Incorporated (Nasdaq: VPHM ... Phase 1 study of VP20621 (non-toxigenic Clostridium difficile ... Clostridium difficile infections (CDI), a common and dangerous ... of antibiotic medications.  VP20621 contains the spores of a ...
Cached Medicine Technology:Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 2ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 3ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 5ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 6
(Date:8/28/2015)... ... ... For Dallas, the time is nearing for the annual Heart Walk, and ... The American Heart Association hosts their well-known Heart Walk to raise money in awareness ... can be made. Walkers can participate in the cause and someone can also donate, ...
(Date:8/28/2015)... ... August 28, 2015 , ... On May 30th, 2015, Best Drug ... of the “Music With A Mission” benefit concert in Mendon, IL. Held in the ... raise money to support music education programs in the underfunded local school districts of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Altima Technologies, Inc., the ... and data center assets and audio-video devices, recently released Visio Stencils for the ... HP ProLiant Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... three-year accreditation for its adolescent residential, counseling, day treatment and intensive family based ... meets international standards for quality and its pursuit of excellence. As a nonprofit ...
(Date:8/28/2015)... Northridge, CA (PRWEB) , ... August 28, 2015 , ... ... special price on Zoom teeth whitening. For just $199, patients can currently receive a ... to traditional in-office teeth whitening procedures, but it includes a number of unique features ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3Health News:West Ridge Academy Awarded CARF Three-Year Accrediation 2Health News:Northridge Dentists Dr. Elyson and Dr. Assili Now Offer a Special Promotion on Zoom Teeth Whitening 2
... , , , , ... Cleveland Clinic Lou Ruvo Center for Brain Health welcomes ... highly touted model of patient-focused care. , , ... Health is a highly specialized clinical center designed to advance the research, early ...
... Va., July 13 Long term care costs in most ... putting significant financial pressure on those in or near retirement. ... Genworth offers a suite of insurance products to help people ... in Arkansas can take advantage of a new program designed ...
... , , , ... BMRN ) announced today that patient enrollment has been ... 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder ... company expects to report initial results in the first half of ...
... of lives, researchers say , MONDAY, July 13 (HealthDay ... have died because of safety restrictions on the ... study suggests. , Finnish researchers concluded that clozapine is ... antipsychotics. , For this study, the researchers looked at ...
... , LOS ALTOS, Calif., July 13 InteKrin ... as Chief Business Officer. Most recently, Mr. Parker served as ... Goldman, Sachs & Co. Over the past ten years, Mr. ... which time he advised many of the biotechnology industry,s leading companies. ...
... (NYSE: HAE ) will announce its Q1FY10 earnings on August 3, ... , Webcast Link: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=2323195 ... from August 3, 2009 after 1:00 pm to August 10, 2009. , ... Julie Fallon, Tel. (781) 356-9517, Alt. Tel. ...
Cached Medicine News:Health News:Cleveland Clinic Lou Ruvo Center for Brain Health Opens for Business 2Health News:Cleveland Clinic Lou Ruvo Center for Brain Health Opens for Business 3Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Arkansas AARP Members 2Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Arkansas AARP Members 3Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Arkansas AARP Members 4Health News:Genworth Financial Simplifies the Process of Purchasing Affordable Long Term Care Insurance for Arkansas AARP Members 5Health News:Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio A Syndrome 2Health News:Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio A Syndrome 3Health News:Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio A Syndrome 4Health News:Schizophrenia Drug Got Bad Rap 2Health News:InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief Business Officer 2
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump....
The original battery-operated suction and irrigation system features a new ergonomic hand piece and superior performance characteristics that have increased the overall flow rate....
... The first step to treatment is ... is an innovative and quick, patient-friendly tool ... female urinary incontinence while minimizing patient discomfort. ... device features a new type of urethral ...
...
Medicine Products: